dose was gradually increased from 450 to 500 mg/day. The frequency of her seizures decreased 2 weeks after receiving modified treatment. The urinary 6080143_0027-OHF/F ratio gathered over 24 hours was measured and compared with the value from before she left our hospital the first time1).
Methods
The patient's genotype of the metabolic enzymes of phenytoin had been judged to be CYP2C9 *1/*1 and C YP2C19 *1/* 2 1). The pharmacokinetic parameters of phenytoin were estimated from serum phenytoin concentrations in the toxic area, with the use of subpopulation parameters of CYP2C9*1/*1 and CYP2C9 *1/* 34). The typical predicted dose of phenytoin was calculated from equation (1) (below) , based on these estimated parameters. The percentage of deviation between the predicted dose and the administered dose was calculated from equation (2) (below).
Each alteration of carbamazepine and clonazepam clearance was estimated to evaluate the pharmacokinetic influence of these agents on porphyria.
In the second hospitalization, the alteration of carbamazepine and clobazam clearances was estimated. The alteration of the N-desmethylclobazam/clobazam ratio was also evaluated, because clobazam is metabolized to N-desmethylclobazam by CYP3A4. The original data used for this study were obtained as described previously1).
Her pharmacokinetic parameters of anticonvulsants were estimated by the software PEDA (parameter estimation and dosage adjustment) 5) incor- 2. Alteration of the clearance of carbamazepine and clonazepam The decrease in carbamazepine clearance (Fig.  2) leads us to conjecture that the suppression of CYP biosynthesis was brought on by a mechanism similar to that of the metabolic saturation of phenytoin by the concomitant phenytoin. In addition, an increase in carbamazepine clearance was transiently observed (Fig. 2) , which might have been due to a high blood concentration of carbamazepine resulting from the improvement of the equilibrium of CYP biosynthesis, because a month had passed after the discontinuation of phenytoin.
The results suggest that phenytoin markedly affected CYP biosynthesis in this patient with porphyria. The influence on CYP might have caused saturation of phenytoin metabolism and an excessive decrease in carbamazepine clearance. The clonazepam clearance (CL/F) was estimated to be approximately 4.3 L/hr as the mean value (Fig. 2) . The total body clearance (CLtot) is calculated to be 4.4 L/hr because the bioavailability of clonazepam is reported to be approximately 0.989). The product of the value of unbound fraction and the hepatic intrinsic clearance was calculated to be 4.4 L/hr from equation (5) when the absorption ratio was regarded to be 1.0 according to the high bioavailability (see "Appendix") . The general value of hepatic blood flow is about 90 L/hr. Therefore, the hepatic extraction ratio of clonazepam was calculated to be approximately 0.05 from equation (7) (see "Appendix") . Clonazepam is considered to be a metabolic capacity-limited agent, according to the calculated value of the hepatic extraction ratio. Carbamazepine is a similar type agent. Carbamazepine clearance seems to be excessively affected by the alteration of hepatic CYP3A4 activity, whereas the clonazepam clearance was not altered in spite of concomitant phenytoin.
The metabolic pathway of clonazepam proceeds by nitroreduction, acetylation, and hydroxylation.
The acetylation is reported to be affected by the polymorphic N-acetyltransferase (NAT) that determines the acetylation phenotype of the individual10). This patient was considered to be an intermediate acetylator since her genotype was NAT2*4/*6. There has been no report of a relationship between the NAT2 genotype and a phenotype of clonazepam pharmacokinetics. The influence of the NAT2 genotype on the alteration of clonazepam clearance was unclear.
Seree et al, suggested that the nitroreduction of clonazepam is catalyzed by CYP3A411). Therefore, clonazepam metabolism might also be affected by the suppression of CYP biosynthesis (Fig. 2) . However, the alteration of clonazepam and carbamazepine clearances was different. Binding plasma proteins of phenytoin, clonazepam, and carbamazepine is 90-95%, 80-90%, and 70-80%, respectively12,13). This result implies that the difference in the affinity ratio of binding to plasma proteins affects the alteration of these clearances.
Pharmacokinetic evaluation of anticonvulsants after the second hospitalization
The patient's medication after the second hospitalization was evaluated according to the alteration of carbamazepine clearance, clobazam clearance, and the N-desmethylclobazam/clobazam ratio (Table) . The carbamazepine and clobazam clearances and N-desmethylclobazam/clobazam ratio were unaltered after re-hospitalization.
However, the measured value of the urinary 6/3-OHF/F ratio was slightly high compared with the value (15.4) before the patient left our hospital the first time1.
Her condition had not improved with a carbamazepine dose of 450 mg/day (see "Case"), whereas the frequency of seizures decreased by increasing the carbamazepine dose to 500 mg/day. Carbamazepine was considered to be effective and safe at a dose of 500 mg/day. The dosage regimen after the second hospitalization was considered to have been appropriately modified as a result.
Conclusions
From the Pharmacokinetic evaluations for this patient, the following conclusion was established: phenytoin was not a proper medication. Carbamazepine was effective and safe, within a moderate 
